1987
Parotid Gland Salivary Secretion in Tourette's Syndrome and Attention Deficit Disorder: A Model System for the Study of Neurochemical Regulation
COHEN D, ORT S, CARUSO K, ANDERSON G, HUNT R, SHAYWITZ B, KREMENITZER M, LECKMAN J. Parotid Gland Salivary Secretion in Tourette's Syndrome and Attention Deficit Disorder: A Model System for the Study of Neurochemical Regulation. Journal Of The American Academy Of Child & Adolescent Psychiatry 1987, 26: 65-68. PMID: 3034852, DOI: 10.1097/00004583-198701000-00013.Peer-Reviewed Original ResearchConceptsAttention deficit disorderTourette syndromeSalivary amylase concentrationTS patientsAmylase concentrationSalivary secretionNeurochemical regulationReceptor functioningTreatment of TSDeficit disorderSalivary amylase secretionParotid gland secretionSingle dosesSalivary volumeClonidinePatientsAmylase secretionSyndromeADD patientsSalivary measuresSecretionTotal amylaseSalivary amylaseDisordersChildren
1986
Rebound Phenomena in Tourette's Syndrome After Abrupt Withdrawal of Clonidine: Behavioral, Cardiovascular, and Neurochemical Effects
Leckman J, Ort S, Caruso K, Anderson G, Riddle M, Cohen D. Rebound Phenomena in Tourette's Syndrome After Abrupt Withdrawal of Clonidine: Behavioral, Cardiovascular, and Neurochemical Effects. JAMA Psychiatry 1986, 43: 1168-1176. PMID: 3465278, DOI: 10.1001/archpsyc.1986.01800120054011.Peer-Reviewed Original ResearchConceptsTourette syndromeNeurochemical effectsAbrupt withdrawalWorsening of ticsClonidine therapyClonidine withdrawalClonidine's effectivenessAdrenergic mechanismsBlood pressureOpen trialTic symptomsUrinary excretionPlasma levelsMotor restlessnessHomovanillic acidClonidine hydrochlorideSyndromeWithdrawal periodPrewithdrawal levelsRebound phenomenonPatientsPulse rateClonidineWithdrawalNorepinephrine
1984
Whole blood serotonin and tryptophan levels in Tourette's disorder: Effects of acute and chronic clonidine treatment
Leckman J, Anderson G, Cohen D, Ort S, Harcherik D, Hoder E, Shaywitz B. Whole blood serotonin and tryptophan levels in Tourette's disorder: Effects of acute and chronic clonidine treatment. Life Sciences 1984, 35: 2497-2503. PMID: 6595491, DOI: 10.1016/0024-3205(84)90435-1.Peer-Reviewed Original ResearchConceptsChronic clonidine treatmentClonidine treatmentTourette's disorder patientsWhole blood serotoninDisorder patientsTourette's disorderBlood serotoninTryptophan levelsMean differenceChronic treatmentAcute doseNormal controlsMean increaseClonidinePatientsDisordersMode of actionTreatmentSignificant differencesSerotoninBaseline conditionsLevelsDifferencesDoseParotid Salivary Response to Clonidine in Tourette's Syndrome: Indicator of Adrenergic Responsivity
SELINGER D, COHEN D, ORT S, ANDERSON G, CARUSO K, LECKMAN J. Parotid Salivary Response to Clonidine in Tourette's Syndrome: Indicator of Adrenergic Responsivity. Journal Of The American Academy Of Child & Adolescent Psychiatry 1984, 23: 392-398. PMID: 6205037, DOI: 10.1016/s0002-7138(09)60316-2.Peer-Reviewed Original ResearchConceptsDrug-free patientsSalivary volumeTS patientsTourette syndromeSingle doseAdrenergic receptorsLong-term clonidine treatmentAmylase secretionGood therapeutic responseYoung male patientParotid salivary responseAdrenergic responsivityClonidine treatmentSalivary amylase concentrationMale patientsTherapeutic responseNoradrenergic functioningAmylase concentrationPatientsClonidineParotid glandSyndromeSalivary responseT patientsTotal secretion
1981
Plasma free MHPG and neuroendocrine responses to challenge doses of clonidine in Tourette's Syndrome: Preliminary report
Young J, Cohen D, Hattox S, Kavanagh M, Anderson G, Shaywitz B, Maas J. Plasma free MHPG and neuroendocrine responses to challenge doses of clonidine in Tourette's Syndrome: Preliminary report. Life Sciences 1981, 29: 1467-1475. PMID: 6946271, DOI: 10.1016/0024-3205(81)90012-6.Peer-Reviewed Original ResearchConceptsFree MHPGPlasma free MHPGTourette syndromeChallenge doseNeuroendocrine responsesDoses of clonidineSingle oral dosesClonidine administrationResponsive patientsGH responseOral dosesMaintenance treatmentThyroxine indexClonidineTS patientsPatientsMHPGSyndromeT patientsNeuropsychiatric patientsPilot studyPreliminary reportMetabolic responseFurther investigationDose